Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03659929 · ClinicalTrials.gov registry record · Phase 3
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
A Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT03659929 is a Phase 3 study of Attention Deficit Hyperactivity Disorder that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 320 participants, above the 203-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (58% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT03659929, a Phase 3 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amphetamine Sulfate
Study Locations (20)
Florida
- 108: Meridien Research - Bradenton
- 103: Gulfcoast Clinical Research Center - Fort Myers
- 129: Sarkis Clinical Trials - Gainesville
- 105: Meridien Research - Lakeland
- 120: Meridien Research - Maitland
- 130: Medical Research Group of Central Florida - Orange City
- 123: APG Research, LLC - Orlando
- 115: Clinical Neuroscience Solutions (CNS), Inc. - Orlando
California
- 114: Pharmacology Research Institute - Encino
- 133: Collaborative Neuroscience Network - Garden Grove
- 124: Pharmacology Research Institute - Newport Beach
Michigan
- 134: Rochester Center for Behavioral Medicine - Rochester Hills
- 128: Clinical Neurophysiology Services - Sterling
New Jersey
- 116: Alliance - Hassman Research Institute - Berlin
- 127: Center for Emotional Fitness - Cherry Hill
Connecticut
- 121: CT Clinical Research Associates - Cromwell
Georgia
- 104: Northwest Behavioral Research Center - Marietta
Idaho
- 131: Advanced Clinical Research, Inc. - Meridian
Illinois
- 113: Capstone Clinical Research - Libertyville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03659929
The ClinicalTrials.gov registry entry for NCT03659929 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (58% higher). The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03659929 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT03659929 about?
NCT03659929 is a clinical study titled "Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate". The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
What is the current status of trial NCT03659929?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2018-09-18. Estimated completion is 2019-04-12.
What conditions does trial NCT03659929 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT03659929?
The interventions under investigation include: Placebo (DRUG), Amphetamine Sulfate (DRUG).
Who is sponsoring clinical trial NCT03659929?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03659929 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
-
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
COMPLETED · Phase 3
-
A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.